CD19 and congenital rubella syndrome: observed increases in F4/80int-loLy6Cint-hi macrophages, which, following administration of mCD40L CD19 CAR T-cells engineered to further engage macrophages, led to markedly increased macrophage numbers, CRS symptoms, and mortality.